Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetraarsenic oxide
- Development stage
- Preclinical
- Lead developer
- Komipharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tetraarsenic oxide (As4O6), also known as TAO or KML001, is an inorganic arsenic compound investigated for its antineoplastic and anti-angiogenic properties. It is chemically distinct from the more common arsenic trioxide (As2O3) due to its cage-like dimeric structure. TAO demonstrates anti-cancer activity through multiple mechanisms, including the inhibition of the Akt signaling pathway in cancer cells and the downregulation of Matrix Metalloproteinase-2 (MMP-2) and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) in endothelial cells, which collectively suppress tumor growth and angiogenesis. Additionally, it has been shown to modulate autophagy in cancer cells. Developed primarily by Komipharm International, TAO has been evaluated in clinical trials for various malignancies, including prostate cancer and glioblastoma, and has shown preclinical efficacy in cervical cancer models.
- Brand names
- Tetras
- Other names
- tetraarsenic hexoxideAs4O6As-4O6As 4O6
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)VEGFR2 (Vascular endothelial growth factor receptor 2)MMP2 (Matrix metalloproteinase-2)
Beyond the preview
Go deeper on tetraarsenic oxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetraarsenic oxide.